Key Takeaways GSK's Q3 core EPS rose 11% as sales climbed 7% to $11.52B, surpassing consensus estimates.HIV, oncology and respiratory drugs drove results, led by Dovato, Cabenuva and Jemperli.GSK raised 2025 guidance, now expecting 6-7$1.48 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.26. Core earnings increased 11% year over year on a reported basis and 14% at a cons ...